Effect of etidronate disodium on bone turnover following surgical menopause.
A longitudinal study was performed to document the effect of surgical menopause and postmenopausal etidronate disodium therapy on several nonhistomorphometric indices of bone turnover. Twenty healthy, premenopausal women undergoing oophorectomy for nonmalignant conditions were studied preoperatively and at 3 monthly intervals postoperatively. Sequential measurements of serum calcium (Ca), alkaline phosphatase (AP), bone Gla protein (BGP), and urinary calcium and hydroxyproline excretion, expressed as a ratio of urinary creatinine (UCa/Cr and UOHp/Cr, respectively) were obtained. Twenty-four-hour whole body retention of diphosphonate (WBR) and radial bone density were also measured. When a postoperative increase in bone turnover was observed, patients were randomized to receive either 400 mg etidronate disodium daily or placebo for 3 months. Oophorectomy was associated with a significant increase in WBR, Ca, AP, and BGP and an insignificant rise in UCa/Cr. A variable pattern of UOHp/Cr was seen. Patients on placebo maintained these elevated levels of Ca, BGP, and UCa/Cr. WBR and AP continued to rise. Etidronate disodium therapy resulted in a fall towards premenopausal levels in WBR, Ca, and UCa/Cr. AP and BGP were unchanged. Three months after stopping etidronate, BGP fell significantly and the decrease in Ca was maintained; however, WBR and UCa/Cr had returned towards pretreatment values. Bone density measurements did not change significantly. An increase in several of the indices of bone turnover was seen following oophorectomy. Etidronate disodium suppressed this increase, affecting indices of both resorption and formation.(ABSTRACT TRUNCATED AT 250 WORDS)
Smith
M L
ML
Department of Medicine, Royal Infirmary, Glasgow.
Fogelman
I
I
Hart
D M
DM
Scott
E
E
Bevan
J
J
Leggate
I
I
D000469:Alkaline Phosphatase / Q000097:blood; D001842:Bone and Bones / Q000378:metabolism*; D002118:Calcium / Q000097:blood / Q000652:urine; D002135:Calcium-Binding Proteins / Q000097:blood; D012968:Etidronic Acid / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007044:Hysterectomy; D008593:Menopause / Q000502:physiology*; D008875:Middle Aged; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; D015675:Osteocalcin; D010024:Osteoporosis / Q000517:prevention & control; D010052:Ovariectomy; D013667:Technetium
D002135:Calcium-Binding Proteins; D009942:Organometallic Compounds; D015609:Organotechnetium Compounds; C036811:technetium Tc 99m (Sn) etidronate; D015675:Osteocalcin; D013667:Technetium; D000469:Alkaline Phosphatase; D012968:Etidronic Acid; D006909:Hydroxyproline; D002118:Calcium